13th HPAPI: Process Development for Highly Potent Drugs
The rise in novel, more potent compounds, alongside EU Annex 1, are mounting pressure on biopharma, CDMOs and equipment providers to evolve their industrial hygiene, process engineering and manufacturing capabilities to ensure safe handling and effective scale-up to achieve commercial GMP manufacturing. The 13th HPAPI: Process Development for Highly Potent Drugs Summit (June 25-29 | Philadelphia, PA) is your definitive community to evaluate efficient high potent compounds synthesis, adoption of innovative technology platforms and occupational safety best practice.
Be one of the first to see the brand-new Event Guide with our star speaker faculty here: https://ter.li/295kjb
Built on 12 years, this is your must-attend summit to network with 130+ like-minded individuals to
- Expedite safe, efficient clinical and commercial manufacturing of novel high potent drugs
- Explore and validation new containment solutions and technologies to optimize process development and manufacturing
- Increase your multi-product facility flexibility through robust design, and mitigate cross contamination with cleaning validation
- Effectively implement bullet-proof risk assessment of occupational exposure, and reporting system to comply with EU Annex 1
Join 130+ experts from the likes of Merck, Gilead, Eli Lilly and find out more here: https://ter.li/295kjb
